Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

IPO Year: 2019

Exchange: NASDAQ

Website: galeratx.com